The anticipation of pending legislation that will allow a pathway for the FDA to approve follow-on biologics presents a potential boon for insulated packaging providers and other supply chain partners.

The September issue Advanced Degrees column in Contract Pharma is the second in a two-part series on biosimilars and cautions those who may be fool-hearty enough to try and shortcut qualifying thermal packaging for biosimilars.

You can link directly to the article here.